Therefore, strategies to inhibit global IL-6 signaling pathways based on antibodies and small molecules that target IL-6, IL-6R, or the downstream signaling JAKs have shown beneficial cardiovascular effects when used as treatment options for chronic inflammatory diseases, COVID-19, and life-threatening cytokine storms associated with CAR T cell therapy in patients with cancer [122,131]. The gene discussed is IL6; the disease is COVID-19.